Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Characterization of a human-mouse chimeric monoclonal antibody targeting rabies virus glycoprotein
  • +7
  • Meina Cai,
  • Ziliang Hu,
  • Yi Yang,
  • Ting Mao,
  • Yacui Liu,
  • Guangwen Lu,
  • Fanli Yang,
  • Jianxun Qi,
  • Weijin Huang,
  • Youchun Wang
Meina Cai
National Institutes for Food and Drug Control
Author Profile
Ziliang Hu
Anhui University Institute of Physical Science and Information Technology
Author Profile
Yi Yang
Biocytogen Pharmaceuticals (Beijing) Co Ltd
Author Profile
Ting Mao
Biocytogen Pharmaceuticals (Beijing) Co Ltd
Author Profile
Yacui Liu
Biocytogen Pharmaceuticals (Beijing) Co Ltd
Author Profile
Guangwen Lu
Sichuan University West China Hospital
Author Profile
Fanli Yang
Sichuan University West China Hospital
Author Profile
Jianxun Qi
University of Chinese Academy of Sciences
Author Profile
Weijin Huang
National Institutes for Food and Drug Control
Author Profile
Youchun Wang
National Institutes for Food and Drug Control

Corresponding Author:[email protected]

Author Profile

Abstract

At present, the horse or human rabies immunoglobulin (RIG) used for post-exposure prevention of human rabies (PEP) has high cost and limited availability. It is strongly encouraged to replace RIG with equivalent or more effective and safer products. Mouse and human monoclonal antibodies have been shown to protect rodents from lethal rabies virus (RABV) attacks. In this study, we reported a human-mouse chimeric monoclonal antibody, 12-2A12, which showed a strong neutralization potency and a wide breadth against multiple street viruses of RABV in vitro. The antibody binds the viral glycoprotein (G) with nanomolar affinity. The complex structure of 12-2A12 bound to RABV G reveals that the antibody recognizes an epitope that partially overlaps with the recognition region for the nicotinic acetylcholine receptor (nAChR). The antibody therefore would interfere with the nAChR/G interaction to block the viral receptor binding. In addition, comparison of our complex structure with the G structure in the acidic state reveals a clear steric clash, highlighting that the antibody would further prevent the conformational changes of the viral glycoprotein that are essential for membrane fusion. In light of these functional and structural data, we believe that 12-2A12 might be developed to be included in an antibody cocktail for potential use in human rabies PEP.
03 Apr 2023Submitted to Journal of Medical Virology
07 Apr 2023Submission Checks Completed
07 Apr 2023Assigned to Editor
07 Apr 2023Review(s) Completed, Editorial Evaluation Pending
12 Apr 2023Reviewer(s) Assigned
04 Jun 2023Editorial Decision: Revise Minor
29 Jun 20231st Revision Received
30 Jun 2023Review(s) Completed, Editorial Evaluation Pending
30 Jun 2023Submission Checks Completed
30 Jun 2023Assigned to Editor
30 Jun 2023Editorial Decision: Accept